The way property values are displayed:
The way concept relations are shown:
The way concept relations are shown:
Anistreplase
Hierarchy: | ∟ ∟ ∟ ∟ ∟ ∟ Anistreplase 4 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Anistreplase 4 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Anistreplase 4 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Anistreplase 4 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Anistreplase 4 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Anistreplase 4 coordinate concepts∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ ∟ Anistreplase 4 coordinate concepts∟ ∟ ∟ ∟ |
Broader terms: | |
History note: | |
historyNote*: | 91
X |
publicMeSHNote*: | 91
X |
Scope note: | An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for URINARY PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
X |
activeMeSHYear*: | |
dateCreated*: | 1990-05-07X |
dateEstablished*: | 1991-01-01X |
dateRevised*: | 2005-06-30X |
recordAuthorizer*: | sjnX |
recordMaintainer*: | ssbX |
recordOriginator*: | RLSX |
Type: | |
Coordinate terms: | |
URI: | |
Labels and equivalent concepts: | Anistreplaasi (fi) XAnistreplas (sv) Roberts Brand of Anistreplase (en, replaced) SmithKline Beecham Brand of Anistreplase (en, replaced) Reusch Brand of Anistreplase (en, replaced) Monmouth Brand Anistreplase (en, replaced) APSAC (en, replaced) Madaus Brand of Anistreplase (en, replaced) Anisoylated Plasminogen-Streptokinase Activator Complex (en, replaced) |
Share: |
Loading results...